Clinical Trial Update: A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating IMC-A12 (avelumab?) in participants with advanced solid tumors; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• IMC-A12 (cixutumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2018-10-22